

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 6

Complete if Known

Application Number	10/586,501
Filing Date	September 14, 2007
First Named Inventor	Martin Hendrix
Art Unit	1624
Examiner Name	Deepak R. Rao
Attorney Docket Number	01-2118

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)				
	A1	US- 5 041 449		09-20-1991	BELLEAU ET AL.	
	A2	US- 5 047 407		09-10-1991	BELLEAU ET AL.	
	A3	US- 5 053 499		10-01-1991	KOJIMA ET AL.	
	A4	US- 5 270 315		12-14-1993	BELLEAU	
	A5	US- 5 294 612		03-15-1994	BACON ET AL.	
	A6	US- 5 466 806		11-14-1995	BELLEAU ET AL.	
	A7	US- 5 541 187		07-30-1996	BACON ET AL.	
	A8	US- 5 563 049		10-08-1996	KOJIMA ET AL.	
	A9	US- 5 656 629		08-12-1997	BACON ET AL.	
	A10	US- 5 684 164		11-04-1997	BELLEAU ET AL.	
	A11	US- 5 750 673		05-12-1998	MARTIN	
	A12	US- 5 969 116		10-19-1999	MARTIN	
	A13	US- 5 977 332		11-02-1999	MARTIN	
	A14	US- 5 977 118		11-02-1999	BACON ET AL.	
	A15	US- 6 100 037		08-08-2000	PHILLIPS ET AL.	
	A16	US- 6 175 008		01-16-2001	BELLEAU ET AL.	
	A17	US- 6 174 884		01-16-2001	HANING ET AL.	
	A18	US- 6 211 158		04-03-2001	SEELA ET AL.	
	A19	US- 6 225 315		05-01-2001	ELLIS	
	A20	US- 2001 0041797		11-15-2001	BELLEAU ET AL.	
	A21	US- 2001 0044441		11-22-2001	CAMPBELL ET AL.	
	A22	US- 6 350 753		02-26-2002	BELLEAU ET AL.	
	A23	US- 2002 058635		05-16-2002	AVERETT	
	A24	US- 2002 0132754		09-19-2002	BOSS ET AL.	
	A25	US- 6 458 796		10-01-2002	HANING ET AL.	
	A26	US- 6 479 463		11-12-2002	WANG ET AL.	
	A27	US- 2003 0087918		05-08-2003	BELLEAU ET AL.	
	A28	US- 2004 185459		09-23-2004	OTSUKA ET AL.	
	A29	US- 2004 0220186		11-04-2004	BELL ET AL.	
	A30	US- 6 831 174		12-14-2004	BELLEAU ET AL.	
	A31	US- 2004 0254201		12-16-2004	BELLEAU ET AL.	
	A32	US- 6 903 224		06-07-2005	BELLEAU ET AL.	
	A33	US- 2005 209251		09-22-2005	LINKER ET AL.	
	A34	US- 7 737 156		05-11-2006	BOSS ET AL.	
	A35	US- 7 067 507		06-27-2006	PULLEY ET AL.	
	A36	US- 7 122 693		10-17-2006	BELLEAU ET AL.	
	A37	US- 2006 259651		11-16-2006	LINSCHOTEN ET AL.	
	A38	US- 2007 0037977		02-15-2007	BELLEAU ET AL.	
	A39	US- 2007 0105881		05-10-2007	HENDRIX ET AL.	
Examiner Signature				Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in accordance with MPEP 609. Draw line through citation if not in accordance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. *Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 6

Complete if Known

Application Number	10/586,501
Filing Date	September 14, 2007
First Named Inventor	Martin Hendrix
Art Unit	1624
Examiner Name	Deepak R. Rao
Attorney Docket Number	01-2118

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A40	US- 7 488 733	05-10-2007	HENDRIX ET AL.	
	A41	US- 2009 0111838	04-30-2009	HENDRIX ET AL.	
	A42	US- 2010 0035900	02-11-2010	HENDRIX ET AL.	
	A43	US- 2010 0210839	08-19-2010	BOESS ET AL.	
	A44	US- 2011 0015193	01-20-2011	EICKMEIER ET AL.	
	A45	US- 2011 0085730	03-17-2011	HENDRIX ET AL.	
	A46	US- 2011 0082137	04-07-2011	GIOVANNINI ET AL.	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	B1	GB-937 724	09-25-1963	CIBA LTD		
	B2	CH-396 924	08-15-1965	CIBA GEIGY		A34
	B3	CH-396 925	08-15-1965	CIBA GEIGY		A34
	B4	EP-0 130 735	01-09-1985	AMERICAN HOME PROD		
	B5	EP-0 286 028	10-12-1988	BOEHRINGER MANNHEIM GMBH		B8
	B6	DE-4 004 558	09-27-1990	SANYO KOKUSAKU PULP CO		A3
	B7	EP-496 617	07-29-1992	GENSIA PHARMA		
	B8	CA-1 311 201	12-08-1992	BOEHRINGER MANNHEIM GMBH		
	B9	WO-94 14802	07-07-1994	BELLEAU PIERRETTE & HF		
	B10	WO-94 17803	08-18-1994	GENSIA INC		
	B11	EP-0 626 387	11-30-1994	CIBA GEIGY AG		
	B12	EP-0 679 657	11-02-1995	CIBA GEIGY AG		A11
	B13	WO-97 16456	05-09-1997	CHONG KUN DANG CORP		
	B14	WO-97 46569	12-11-1997	CIBA GEIGY AG		
	B15	WO-98 00434	01-08-1998	CIBA GEIGY AG		
	B16	WO-98 16184	04-23-1998	ICN PHARMACEUTICALS		
	B17	WO-98 40384	09-17-1998	BAYER AG		
	B18	JP-11-501923	02-16-1999	SANOI WINTHROP INC.		
	B19	WO-2000 043394	07-27-2000	USTAV EXPERIMENTALRI BOTANIKY AV CR		
	B20	WO-2001 05758	01-25-2001	NPS ALLELIX CORP		
	B21	WO-2001 060315	08-23-2001	BIOCHEM PHARMA INC		

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). * See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two letter code (WIPO Standard ST 3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. * Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 6

Complete if Known

Application Number	10/586,501
Filing Date	September 14, 2007
First Named Inventor	Martin Hendrix
Art Unit	1624
Examiner Name	Deepak R. Rao
Attorney Docket Number	01-2118

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ² - Number ³ - Kind Code ⁴ (if known)				
	B22	JP-2001 514838	09-11-2001	BAYER AG		A17
	B23	WO-2001 077075	10-18-2001	INOTEK CORP		
	B24	WO-2002 16348	02-28-2002	ASTRAZENECA AB		
	B25	WO-2002 057425	07-25-2002	MERCK & CO INC		
	B26	JP-2002 523507	07-30-2002	Bayer AG		A25
	B27	WO-2002 074774	09-26-2002	PFIZER LTD		
	B28	WO-2002 086160	10-31-2002	MITSUBISHI RAYON CO		A28
	B29	WO-2003 011925	02-13-2003	PPG IND OHIO INC		
	B30	WO-2003 022859	03-20-2003	EPOCH BIOSCIENCES INC		
	B31	CA-2 466 824	05-08-2003	PFIZER		
	B32	WO-2003 037432	05-08-2003	PFIZER PROD INC		
	B33	WO-2003 072757	09-04-2003	BIOTA INC		
	B34	WO-2003 099840	12-04-2003	ISIS PHARMACEUTICALS INC		
	B35	WO-2004 002999	01-08-2004	IDENIX CAYMAN LTD		
	B36	CA-2 496 194	03-04-2004	BAYER HEALTHCARE AG		
	B37	DE-102 38 722	03-11-2004	BAYER AG		A34
	B38	WO-2004 046331	06-03-2004	IDENIX CAYMAN LTD		
	B39	EP-1 460 077	09-22-2004	JORDANIAN PHARMACEUTICAL MFG		
	B40	JP-2004 536933	12-09-2004	PPG IND OHIO INC		B29
	B41	WO-2004 108139	12-16-2004	AREXIS AB		A37
	B42	WO-2004 113306	12-29-2004	BAYER HEALTHCARE AG		A40
	B43	WO-2005 051944	06-09-2005	UNIV CONNECTICUT		
	B44	JP-2005 531549	10-20-2005	BAYER CROPSOURCE AG		A33
	B45	JP-2006 201272	01-12-2006	TAMURA SEISAK		A34
	B46	JP-2006 503051	01-26-2006	BAYER AG		
	B47	WO-2006 076455	07-20-2006	ARENA PHARM INC.		
	B48	WO-2006 084281	08-10-2006	MILLENNIUM PHARM INC		
	B49	WO-2006 091905	08-31-2006	GILEAD SCIENCES INC		
	B50	WO-2006 125548	11-30-2006	BAYER HEALTHCARE AG		C9

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). *See Kind Code of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 4 of 6

Complete if Known

Application Number	10/586,501
Filing Date	September 14, 2007
First Named Inventor	Martin Hendrix
Art Unit	1624
Examiner Name	Deepak R. Rao
Attorney Docket Number	01-2118

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² - Number ³ - Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	B51	WO-2007 025043	03-01-2007	IDENIX PHARMACEUTICALS INC.		
	B52	WO-2007 046747	04-26-2007	ASTRAZENCA AB		
	B53	WO-2008 005542	01-10-2008	GILEAD SCIENCES INC.		
	B54	WO-2008 055959	05-15-2008	GALAPAGOS N V		
	B55	WO-2008 100447	08-21-2008	GILEAD SCIENCES INC.		
	B56	WO-2008 104077	09-04-2008	METHYLGENE INC.		
	B57	WO-2008 139293	11-20-2008	PFIZER		
	B58	WO-2009 068617	06-04-2009	BOEHRINGER INGELHEIM INT		
	B59	WO-2009 121919	10-08-2009	BOEHRINGER INGELHEIM INT		
	B60	WO-2010 026214	03-11-2010	BOEHRINGER INGELHEIM INT		
	B61	WO-2010 112437	10-07-2010	BOEHRINGER INGELHEIM INT		
	B62	WO-2011 018495	02-17-2011	BOEHRINGER INGELHEIM INT		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	C1	Accessed on December 18, 2008, http://en.wikipedia.org/wiki/Amnesia	
	C2	Accessed on December 18, 2008, www.mentalhealth.org.uk/information/mental-health-a-z/dementia	
	C3	BARGER ET AL., "Role of cyclic GMP in the Regulation of Neuronal Calcium and Survival by Secreted Forms of Beta-Amyloid Precursor," J of Neurochem, 1995, Vol. 64, No. 5, pp. 2087-2096	
	C4	BYRN ET AL., Solid State Chemistry of Drugs, 1999, Second Edition, Chapter 11, pp. 232-247	
	C5	Chem Abstracts Service, Database Accession No. ALB-H01677136, Database Chemicals, 2007, XP002556399	
	C6	FRANCIS ET AL., "Cortical Pyramidal Neurone Loss May Cause Glutamatergic Hypoactivity and Cognitive Impairment in Alzheimer's Disease: Investigative and Therapeutic Perspectives," Journal of Neurochemistry, 1993, Vol. 60, No. 5, pp. 1559-1564	
	C7	FRANCIS ET AL., "Glutamatergic systems in Alzheimer's disease," International Journal of Geriatric Psychiatry, 2003, Vol. 18, p. S15-21	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two letter code (WIPO Standard ST 3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. Applicant is to place a check mark here if English language. Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	5	of	6	Complete if Known
				Application Number
				Filing Date
				First Named Inventor
				Art Unit
				Examiner Name
				Attorney Docket Number

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issu number(s), publisher, city and/or country where published.	T ²
	C8	HARB ET AL., "Pyrazoles as building blocks in heterocyclic synthesis," Chemical Papers, 2005, Vol. 59, No. 3, pp. 187-195, XP002498688	
	C9	HENDRIX, M. ET AL., "Use of pyrazolopyrimidine against cardiovascular diseases," Data retrieved from espacenet worldwide database, Publication Date: November 30, 2006; English Abstract of WO-2006 125548	
	C10	HETMAN ET AL., "Isolation and characterization of PDE7B, a..." Proc. Nat. Acad. Sci., 2000, Vol. 97, No. 1, pp. 472-476	
	C11	HUNG ET AL., "A high-yielding synthesis of monalkylhydrazines," Journal of Organic Chemistry, 1981, Vol. 46, pp. 5413-5414	
	C12	International Search Report of PCT/EP2003/08880 dated April 1, 2004, International Filing Date: August 11, 2003, International Publication No. WO 2004 026286	
	C13	Last accessed July 15, 2010http://www.nlm.nih.gov/medlineplus/ency/article/000746.htm	
	C14	MARKWALDER, J. A. ET AL., "Synthesis and Biological Evaluation of 1-Aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one Inhibitors of Cyclin-Dependent Kinases," J. of Med Chemistry, 2004, Vol. 47, pp. 5894-5911, XP002399637	
	C15	PRICKAERTS ET AL., "Effects of two selective phosphodiesterase type 5 inhibitors, sildenafil and vardenafil, on object recognition memory and hippocampal cyclic gmp levels in the rat," Neuroscience, 2002, Vol. 113, No. 2, pp. 351-361	
	C16	PUZZO ET AL., "Amyloid-Beta Peptide Inhibits Activation of the Nitric Oxide/Cgmp/Camp-Responsive Element-Binding Protein Pathway during Hippocampal Synaptic Plasticity," The Journal of Neuroscience, 2005, Vol. 25, No. 29, pp. 6887-6897	
	C17	Related U.S. Patent Application No. 12/855,129 filed August 12, 2010	
	C18	Related U.S. Patent Application No. 12/935,686 filed September 30, 2010	
	C19	Related U.S. Patent Application No. 13/062,625 filed March 7, 2011	
	C20	Related U.S. Patent Application No. 13/099,064 filed May 2, 2011	
	C21	REYMANN ET AL., "The late maintenance of hippocampal LTP: Requirements, phases, 'synaptic tagging', 'late-associativity' and implications," Neuropharmacology, 2007, Vol. 52, pp. 24-40	
	C22	SKIPPER ET AL., "Structure-Activity Relationships Observed on Screening a Series of Pyrazolopyrimidines against Experimental Neoplasms," Cancer Research, 1957, Vol. 17, pp. 579-596	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet **6** of **6**

Complete if Known

Application Number	10/586,501
Filing Date	September 14, 2007
First Named Inventor	Martin Hendrix
Art Unit	1624
Examiner Name	Deepak R. Rao
Attorney Docket Number	01-2118

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C23	TIMBERLAKE ET AL., "Chemistry of Hydrazo-, Azo-, and Azoxy Groups," Patal. 1975, Chapter 4	
	C24	UGARKAR ET AL., "Synthesis and antiviral/antitumor activities of....," Journal of Medicinal Chemistry, 1984, Vol. 27, No. 8, pp. 1026-1030	
	C25	VAN STAVEREN ET AL., Journal of Neurocytology, 2002, Vol. 31, pp. 729-741	
	C28	WANG ET AL., "Identification and characterization of a new human type 9 Cgmp-specific phosphodiesterase-splice variant (PDE9A5) Different tissue distribution and subcellular localization of PDE9A variants," Gene, 2003, Vol. 314, pp. 15-27	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.